Newly Launched Technology Will Be on Display at ASSFN in Nashville from June 1 – 4
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
Animation of a ClearPoint Prism Neuro Laser Therapy System
SOLANA BEACH, Calif., June 01, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.
“Deep Brain Stimulation (DBS) has been proven to be a safe and effective strategy to manage patients with medically intractable Parkinson’s Disease, Essential Tremor, and Dystonia,1” said Dr. Kim Burchiel, Professor of Neurological Surgery at the Oregon Health & Science University. “In its more than 30-year history in the US, this highly effective therapy has been mostly performed in highly specialized neurosurgical centers, which, because of their relative rarity, has resulted in only about 5% of eligible patients being treated.1 The development of the SmartFrame OR is anticipated to be a significant step towards accomplishing the triple aim of achieving excellent outcomes in an accessible and appropriate clinical setting, with broad patient acceptance, because it is expected to allow DBS procedures to be performed in a much larger spectrum of hospitals, by a larger contingent of well-trained neurosurgeons.”
“ClearPoint Neuro’s new SmartFrame OR solution supports stereotactic precision packaged in an efficient, intuitive, and reliable platform,” stated Dr. Andrew Conner, Assistant Professor of Neurosurgery at Oklahoma University. “It has completely changed my DBS practice for the better since its release.”
“This is a truly exciting milestone for ClearPoint, and one that has been years in the making,” commented Joe Burnett, President and CEO at ClearPoint Neuro. “We set out to prove that we are one of the most innovative and focused companies in the Neurosurgery space. We are now walking into the premier stereotactic neurosurgical conference able to demonstrate new laser therapy, new operating room navigation, new brain modeling software, new access products and new drug delivery preclinical and clinical trial services. This is meaningful innovation that will ultimately benefit our surgical customers and most importantly, many new patients around the world.”
At ASSFN, the SmartFrame OR and ClearPoint Prism Neuro Laser Therapy System will be showcased at:
- Special Course 1: Epilepsy Surgery Fundamentals and Challenges on Saturday, June 1st
- Special Course 2: Movement Disorder Surgery Fundamentals and Challenges on Saturday, June 1st
- Meet the Expert Session: Initial Experience with the SmartFrame OR Platform
